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drug-dose combination was calculated in 2006 dollars and was
compared to prices available through the November 2006 FSS.
A savings/pill was calculated to develop a nationally representa-
tive estimate of the societal savings that could be achieved if med-
ications could be obtained for FSS prices instead of current
pricing systems. RESULTS: Substitution of the FSS price could
result in a median annual per person savings in drug expendi-
tures of $308 (interquartile range, $124 to $637) for the
Medicare population, age 65 and above. The potential national
savings among these 8 classes over one year is $10.7 billion (95%
CI $10.0 billion to $11.4 billion). Among Statin medications
alone, the annual savings could be $5.9 billion (95% CI $5.4
billion to $6.4 billion) in this age group. CONCLUSION: Sub-
stantial savings in drug expenditures, in the tens of billions of
dollars, would result if Federal Supply Schedule prices were used
by Medicare in place of these commercially available prices.
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OBJECTIVES: The objective of this study was to estimate per
patient per month (PPPM) costs of medications in the six
Medicare Part D protected classes based on ﬁndings among
Medicare and dual eligible beneﬁciaries with drug coverage prior
to enactment of the beneﬁt. METHODS: Data were from the
Thomson Medstat Marketscan Medicare and Medicaid claims
databases. The study sample was constructed by identifying
patients who were enrolled either in Medicare or dually in
Medicare and Medicaid in 2004. Costs were aggregated within
each class, including patient-paid and plan-paid amounts. These
costs provided the numerators for the PPPM calculations.
Denominators were deﬁned as the aggregated patient months for
only those individuals who ﬁlled a drug within a particular class.
Drugs covered under Part B were excluded. RESULTS: The
classes where generic formulations were available (antidepres-
sants and anticonvulsants) showed lower PPPM costs ($45.31
and $50.97, respectively). The costliest class was the antiretro-
virals ($1028.13) for dual eligible patients including those age
64 and under. Among the dual eligibles over 65, immunosup-
pressants were the costliest ($657.72). In the Medicare group,
the cost of immunosuppressants ($814.86) was substantially
higher than the other ﬁve classes. The PPPM cost over all 6
classes for Medicare was $54.75, for dual eligibles it was
$157.99, and $116.35 for all patients. CONCLUSION: PPPM
costs were not uniformly high among the protected classes. The
claims data in this study allowed a “real world” check of how
much the protected classes may impact the ﬁnances of Part D.
There are differences within the classes between the dual eligible
and Medicare patients, and also within the dual eligibles by age.
This is an important message to policy makers that a change to
the structure of the protected classes in Part D may have differ-
ential effects across and also within classes.
MD3
CHANGES IN PRESCRIPTION USE AND OUT-OF POCKET
COSTSAMONG MEDICARE ELIGIBLE ADULTS, 2005–2006
Yin W1, Basu A1, Zhang JX1, Sun SX2, Lee KY2, Meltzer DO1,
Alexander GC1
1University of Chicago, Chicago, IL, USA, 2Walgreens Health Services,
Deerﬁeld, IL, USA
OBJECTIVES: Few assessments of the Medicare Part D Pre-
scription Drug Beneﬁt have been performed. We examined the
impact of the drug beneﬁt on drug utilization and out-of-pocket
expenditures. METHODS: We used pharmacy claims data from
a large national pharmacy to compare drug utilization and out-
of-pocket expenditures of Medicare eligible seniors in 2005 to
their outcomes in 2006. We used pharmacy customers aged
60–64 during the same period as a control group to capture non-
Medicare related trends in drug utilization and costs occurring
during the study period. The sample represented approximately
5.1 million unique Medicare beneﬁciaries aged 65–90 and 1.8
million unique subjects in the control group who ﬁlled and
obtained at least one prescription in pre-beneﬁt 2005 period.
RESULTS: After adjusting for individual characteristics and
socio-economic characteristics of subjects’ zip code of residence,
preliminary analyses suggest subjects’ annual drug utilization
increased by 5.5% (95% conﬁdence interval [CI] 4.7%–6.2%)
and subjects’ annual out-of-pocket expenditures decreased by
10.6% (CI 9.6%–11.9%) in 2006 as compared to 2005, net of
non-Part D related effects. Dual eligible subjects had little to no
increase in drug utilization. However, they had similar declines
in out-of-pocket expenditures as the broader beneﬁciary popu-
lation. Sensitivity analyses demonstrated that the measured
impact was not due to trend differences among different 
age groups over the study period. CONCLUSIONS: Modest
increases in prescription drug utilization and decreases in out-of-
pocket expenditures occurred for these Medicare seniors fol-
lowing the implementation of the Medicare Part D Prescription
Beneﬁt. Further work is needed to examine these patterns among
other beneﬁciaries and to evaluate the impact of these changes
on health outcomes.
MD4
MEDICAID PREFERRED DRUG LISTS’ COSTS TO PHYSICIANS
Ketcham JD1, Epstein AJ2
1Arizona State University,Tempe, AZ, USA, 2Yale University, New
Haven, CT, USA
OBJECTIVES: To measure costs from complying with Medicaid
preferred drug lists (PDLs) for primary care physicians and 
cardiologists. To quantify the potential costs of a hypothetical
universal PDL for Medicare Part D as of January 2006.
METHODS: During December 2005 and January 2006 we sur-
veyed cardiologists and primary care physicians in 9 states about
their experiences with Medicaid PDLs that covered outpatient
prescriptions for statins and antihypertensives. We calculated the
opportunity cost of time spent by physicians and their staff on
requesting prior authorizations (PAs), appealing rejected PAs,
discussing PDLs with others, tracking changes to PDLs, and
receiving PDL-related training, as well as physicians’ altruistic
costs from suboptimal prescribing decisions. We used compre-
hensive prescription data from Wolters Kluwer Health (WKH)
to generate each physician’s annual prescription volume for
statins and antihypertensives separately by PDL coverage status.
We combined the survey data on PDL-related costs per physi-
cian with the WKH prescription volume data using a bootstrap
simulation to calculate total costs and the average cost per physi-
cian. We calculated the potential costs of a hypothetical univer-
sal Medicare Part D PDL by approximating the number of new
Part D prescriptions affected by PDLs and multiplying by the
survey-based average variable cost per prescription. RESULTS:
There were 986 survey respondents and 47,843 physicians with
WKH data. For statins and hypertensives, PDL cost per pre-
scription averaged $8.02 (95% CI: $7.25–$8.78)—$14.41 (95%
CI: $13.29–$15.53) off-PDL and $6.59 (95% CI: $5.91–$7.28)
on-PDL—leading to average Medicaid PDL costs per physician
of $1110 (95% CI: $1061–$1161) annually. Similar restrictions
for Medicare Part D across all therapeutic classes could have cost
